SCHEMBL3694341

SCHEMBL3694341

Cc1cn([C@@]2(C(=O)O)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TK1 P04183 5/20 0.43
TYMP P19971 1/20 0.42
RNASE1 P07998 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6536213 0.92 TK1 (0.42) TK1TYMP
SCHEMBL28239487 0.91 TK1 (0.41) TK1TYMP
SCHEMBL27651863 0.91 TK1 (0.41) TK1TYMP
SCHEMBL5148089 0.88 RNASE1 (0.46) TK1TYMPRNASE1
SCHEMBL28293851 0.88 TK1 (0.39) TK1TYMPRNASE1
SCHEMBL17224727 0.87 TK1 (0.39) TK1TYMPRNASE1
SCHEMBL8744125 0.86 TK1 (0.38) TK1TYMP
SCHEMBL28040328 0.86 PYGM (0.45) TK1
SCHEMBL5709920 0.85 TK1 (0.40) TK1TYMPRNASE1
SCHEMBL8744135 0.85 TK1 (0.38) TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447934-B1 CARRIER AS A MULTIFUNCTIONAL SYSTEM LIFESOME THERAPEUTICS SL (ES) 2025-08-06 EP claimed
EP-4294365-A1 USE OF A PEMETREXED CONCENTRATE SOLUTION STADA ARZNEIMITTEL AG (DE) 2023-12-27 EP disclosed
EP-4213899-A1 TISSUE ADHESIVE FOR USE IN A TREATMENT METHOD IN WHICH AN OPHTHALMOLOGICAL IMPLANT IS IMPLANTED IN A HUMAN OR ANIMAL PATIENT, AND OPHTHALMOLOGICAL IMPLANTATION SYSTEM Carl Zeiss Meditec AG (DE) 2023-07-26 EP disclosed
WO-2022175463-A1 USE OF A PEMETREXED CONCENTRATE SOLUTION STADA ARZNEIMITTEL AG (DE) 2022-08-25 WO disclosed
EP-4046626-A1 USE OF A PEMETREXED CONCENTRATE SOLUTION STADA Arzneimittel AG (DE) 2022-08-24 EP disclosed
WO-2022058247-A1 TISSUE ADHESIVE FOR USE IN A TREATMENT METHOD IN WHICH AN OPHTHALMOLOGICAL IMPLANT IS IMPLANTED IN A HUMAN OR ANIMAL PATIENT, AND OPHTHALMOLOGICAL IMPLANTATION SYSTEM CARL ZEISS MEDITEC AG (DE) 2022-03-24 WO disclosed
US-20100317004-A1 PROBES Life Technologies Corporation (US) 2010-12-16 US disclosed
EP-1585835-B1 Nucleic acid probes and method for detecting a target nucleic acid sequence comprising two or more cis-located nucleic acid regions DYNAL BIOTECH LTD (GB) 2007-04-18 EP disclosed
US-20060269916-A1 Probes DYNAL BIOTECH INC. 2006-11-30 US disclosed
EP-1585835-A2 NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS Dynal Biotech Limited (GB) 2005-10-19 EP disclosed
WO-2004048611-A2 NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS DYNAL BIOTECH LIMITED (GB) 2004-06-10 WO disclosed
EP-0734391-B1 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS INC (US) 2002-06-12 EP disclosed
EP-1201676-A2 PNA-DNA-PNA chimeric macromolecules ISIS PHARMACEUTICALS, INC. (US) 2002-05-02 EP disclosed
US-6277603-B1 PEPTIDE NUCLEIC ACID (PNA); THE DNA PORTION IS COMPOSED OF SUBUNITS OF AT LEAST ONE 2'-DEOXYNUCLEOTIDES; INCREASED NUCLEASE RESISTANCE; ACTIVATE RNASE H ENZYME, USE FOR IN VITRO MODIFICATION OF RNA ISIS PHARMACEUTICALS, INC. 2001-08-21 US disclosed
EP-0734391-A4 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS INC (US) 1998-02-25 EP disclosed
US-5700922-A INCREASED NUCLEASE RESISTANCE, INCREASED BINDING AFFINITY TO COMPLEMENTARY STRANDS; MEDICAL DIAGNOSIS, THERAPY ISIS PHARMACEUTICALS, INC. (US) 1997-12-23 US disclosed
EP-0734391-A1 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS, INC. (US) 1996-10-02 EP disclosed
WO-1995014706-A1 PNA-DNA-PNA CHIMERIC MACROMOLECULES ISIS PHARMACEUTICALS, INC. (US) 1995-06-01 WO disclosed